Goldman Sachs’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $57.5M | Sell |
|
|||||
|
2025
Q1 | $150M | Buy |
|
|||||
|
2024
Q4 | $36.3M | Buy |
|
|||||
|
2024
Q3 | $30.1M | Sell |
|
|||||
|
2024
Q2 | $45.1M | Buy |
|
|||||
|
2024
Q1 | $40.4M | Sell |
|
|||||
|
2023
Q4 | $36.5M | Sell |
|
|||||
|
2023
Q3 | $32.1M | Sell |
|
|||||
|
2023
Q2 | $60.1M | Buy |
|
|||||
|
2023
Q1 | $41.1M | Buy |
|
|||||
|
2022
Q4 | $24.3M | Sell |
|
|||||
|
2022
Q3 | $23.3M | Sell |
|
|||||
|
2022
Q2 | $25.5M | Sell |
|
|||||
|
2022
Q1 | $43.1M | Buy |
|
|||||
|
2021
Q4 | $46.2M | Sell |
|
|||||
|
2021
Q3 | $50.9M | Buy |
|
|||||
|
2021
Q2 | $44.2M | Sell |
|
|||||
|
2021
Q1 | $56.5M | Buy |
|
|||||
|
2020
Q4 | $38.4M | Sell |
|
|||||
|
2020
Q3 | $62.2M | Sell |
|
|||||
|
2020
Q2 | $48.9M | Sell |
|
|||||
|
2020
Q1 | $48.2M | Sell |
|
|||||
|
2019
Q4 | $90.5M | Sell |
|
|||||
|
2019
Q3 | $87.1M | Sell |
|
|||||
|
2019
Q2 | $110M | Sell |
|
|||||
|
2019
Q1 | $116M | Buy |
|
|||||
|
2018
Q4 | $85.5M | Buy |
|
|||||
|
2018
Q3 | $96.6M | Buy |
|
|||||
|
2018
Q2 | $70.8M | Sell |
|
|||||
|
2018
Q1 | $109M | Buy |
|
|||||
|
2017
Q4 | $111M | Sell |
|
|||||
|
2017
Q3 | $110M | Buy |
|
|||||
|
2017
Q2 | $75.6M | Buy |
|
|||||
|
2017
Q1 | $61M | Sell |
|
|||||
|
2016
Q4 | $52.7M | Sell |
|
|||||
|
2016
Q3 | $59.4M | Buy |
|
|||||
|
2016
Q2 | $54M | Buy |
|
|||||
|
2016
Q1 | $41.4M | Buy |
|
|||||
|
2015
Q4 | $30.2M | Buy |
|
|||||
|
2015
Q3 | $9.22M | Buy |
|
|||||
|
2015
Q2 | $6.54M | Sell |
|
|||||
|
2015
Q1 | $7.87M | Buy |
|
|||||
|
2014
Q4 | $5.4M | Sell |
|
|||||
|
2014
Q3 | $9.52M | Buy |
|
|||||
|
2014
Q2 | $5.95M | Sell |
|
|||||
|
2014
Q1 | $7.27M | Buy |
|
|||||
|
2013
Q4 | $6.29M | Sell |
|
|||||
|
2013
Q3 | $14.4M | Buy |
|
|||||
|
2013
Q2 | $7.63M | Buy |
|